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Key learning points 
• Ferric carboxymaltose (Ferinject®) associated hypophosphataemia is a potentially 
underreported adverse effect in patients treated for iron-deficiency anaemia. 
• Previous literature involving some cases has suggested it is reversible through 
phosphate supplementation, but this further upregulated renal phosphate excretion. 
• Standard acute medicine protocols for treating hypophosphataemia do not apply in 
such instances, and a conservative approach should be adopted. 
• Ferric carboxymaltose (Ferinject®) associated hypophosphataemia appears to usually 
resolve some seven weeks after the iron infusion. 
 
MCQs 
1. Ferric carboxymaltose (Ferinject®) associated hypophosphataemia should primarily be 
managed: 
a. with multiple high dose phosphate infusions 
b. conservatively (watch and wait) 
c. oral phosphate (effervescent tablets) 
d. in accordance with standard hospital protocol for hypophosphataemia 
 
2. Apart from serum phosphate measurement, which other two biochemical measurements 
should definitely be measured to avoid further acute complications? 
a. vitamin D and magnesium levels 
b. vitamin D and calcium levels 
c. calcium and iron levels 
d. calcium and potassium levels  
 
 
 
 
 Abstract 
Ferric carboxymaltose (Ferinject®) is an infusion administered for the treatment of iron 
deficiency anaemia. A number of previous case reports have shown the occurrence of 
hypophosphataemia after Ferinject® treatment, supposedly managed though high dose 
phosphate therapy. This case report highlights the risk associated with, and futility of, 
managing this adverse effect through high dose phosphate infusion. A review of the 
available literature suggests that if hypophosphataemia develops as a result of Ferinject®, 
through upregulation of the renal protein Fibroblast Growth Factor-23, it cannot be readily 
reversed and on average persists for circa 50 days. Acute medical units should be aware of 
this – likely underreported – adverse effect, and avoid treating these hypophosphataemic 
patients with high dose phosphate since it can compound symptoms.  
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 Case report 
In specific scenarios where iron deficiency anaemia patients are intolerant or not 
responding to oral supplementation, parenteral supplementation through intravenous 
infusion of iron is recommended.1,2 Ferric carboxymaltose (Ferinject®) is commonly used 
due to the relatively short infusion time. We present a case of Ferinject®-associated severe 
hypophosphataemia and share the journey experienced by the patient in question. 
Furthermore, we utilise a review of the existing literature to make the case for increased 
awareness and guidelines on this side effect. High dose phosphate replacement is not 
indicated in patients who are admitted to an acute unit with hypophosphataemia related 
to iron infusion.  
A 40-year-old female attended a nurse-led haematology out-patient clinic to receive 1000 
mg Ferinject® iv on 12 November 2019. She had received an identical treatment 12 months 
prior, due to ongoing low haemoglobin levels related to poor absorption of oral iron 
supplementation related to coeliac disease. After the first infusion, she had only noticed an 
improvement in fatigue symptoms after approximately two months. Subsequent to the 
second Ferinject® infusion, day 0, symptoms typical of iron deficiency anaemia had again 
not abated and fatigue, shortness of breath on exertion and dizziness continued. Upon a 
visit to the GP at day 6, blood tests revealed hypophosphataemia (see Figure 1). A 500 mmol 
phosphate infusion was administered in line with local Trust protocol for 
hypophosphataemia. However, serum phosphate levels did not return to within normal 
range, and the above symptoms worsened to a stage where the patient presented to the 
Emergency Department on day 8. There, another 500 mmol phosphate infusion was 
commenced – which had to be reduced to 200 mmol at a much lower infusion rate (from 50 
mmol/hr to 20 mmol/hr) due to an episode of severe hypocalcaemia, resolved by injection 
of calcium 2.25 mmol iv. Based on consultation of selected literature3,4, a further four 200-
500 mmol phosphate infusions were administered and vitamin D supplementation was 
initiated. At this stage, the hospital protocol for phosphate infusion was breached. Due to 
anxiety induced by this episode – particularly the extremely low serum phosphate levels - 
and a putative respective induction effect on serum phosphate levels and inhibitory effect 
on Fibroblast Growth Factor-23 (FGF23) levels, 40 mg/day propranolol was prescribed.5,6 
The main symptoms experienced by the patient were extreme fatigue, a profound sensation 
of pressure on the chest, and severe bone pain. At day 15, after further consultation of the 
literature and correspondence with Prof W Fraser (Director of Norfolk & Norwich University 
Hospital Bone Marker Service), phosphate infusions and propranolol were aborted. Serum 
phosphate levels and urinary phosphate excretion rates eventually returned to within 
normal range by day 42. Vitamin D supplementation and a high-phosphate diet were 
adhered to for a total of eight weeks. Over time, the chest and bone pain (the latter 
extended from sternum to back and all limbs, with added presence of a crushing headache) 
gradually reduced to a mild level by day 50. Overall, the episode resulted in a total of 8 
weeks of sickness absence, with fatigue persisting beyond day 56. 
Could this case of Ferinject®-associated severe hypophosphataemia have been prevented 
and is there a curative therapy for it? In terms of the latter, from the available published 
literature we would conclude that currently this type of hypophosphataemia cannot be 
instantly reversed and that it is a matter of patients ‘sitting it out’. The mechanism that 
underlies the hypophosphataemia, upregulation of FGF23 in the kidneys, is known.7 It 
appears that phosphate therapy further elevates FGF23 levels and thereby phosphate 
excretion; neither vitamin D (or its metabolites) nor propranolol affect FGF23 levels, and are 
therefore unlikely to contribute to correction of Ferinject®-related hypophosphataemia. 
Table 1 summarises published data on Ferinject® hypophosphataemia cases; an 
approximate median of 50 days appears to be the time period for phosphate levels to 
normalise again, regardless of attempts to actively reverse the hypophosphataemia or not. 
Prevention of Ferinject®-associated hypophosphataemia is therefore paramount. A 
potential benefit of measuring serum phosphate levels prior to Ferinject® infusion may be 
useful to avoid treating patients with existing hypophosphataemia. Nonetheless, as shown 
in Table 1, this side effect can also occur in patients with an in-range phosphate level. 
Phosphate measurement after Ferinject® infusion is indicated since the initial 
symptomology related to hypophosphataemia overlaps considerably with those associated 
with iron-deficiency anaemia, and it allows for a more exact quantification of the frequency 
of this debilitating side-effect. Further guidance by NHS Improvement, MHRA, or guidance 
by British Society for Haematology, akin to advice issued in New Zealand by Medsafe8, may 
help to increase awareness amongst haematologists and haematology specialist nurses. An 
addition to hospital phosphate infusion protocols highlighting that patients should be asked 
about recent iron infusions will inform wider medical specialties and avoid phosphate 
infusions where possible. Patients who consider Ferinject® therapy need to be consulted 
about the risk of hypophosphataemia and the average period this may persist. In our case, 
the patient was referred directly from primary care into a nurse-led iron infusion clinic. 
Currently, the Royal College of Nursing does not mention the potential for ferric 
carboxymaltose associated hypophosphataemia in its guideline on iron deficiency and 
anaemia.9 Indeed, the patient in this case study was informed about the potential risk of 
anaphylaxis, but not of the risk of hypophosphataemia. The summary of product 
characteristics for Ferinject® does mention hypophosphataemia (but not that it currently 
cannot be readily reversed), and in most cases this is transient and without clinical 
symptoms, and that those cases requiring medical attention occurred mainly in patients 
with existing risk factors and after prolonged exposure to high-dose intravenous iron.10 
Uncertainty remains about the true extend of the risks involved due to variance in the 
literature.11,12 Systematic recording and reporting of Ferinject® associated 
hypophosphataemia, though the MHRA’s yellow card scheme is indicated to determine 
what the true risk and impact of ferric carboxymaltose associated hypophosphataemia is.  
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MCQs – answers 
1. answer: b 
2. answer: b 
 
 
  
 Figure 1, Timeline of Ferinject® (ferric carboxymaltose) associated hypophosphataemia 
case, highlighting association between renal phosphate excretion rate (dot plot) and 
serum phosphate levels (bar chart)  
 
 
All phosphate measurements were taken around 9 AM, and prior to any phosphate 
infusions. **200 mmol phosphate infusion; * 500 mmol phosphate infusion.  
 
 
Table 1, Overview of publications regarding ferric carboxymaltose associated hypophosphataemia cases. 
Reference 
 
Ferric 
carboxymaltose  
dose [n patients] 
Serum phosphate  
level (mmol/L) 
before infusion 
Phosphate level 
(mmol/L) when 
presenting post-infusion 
Days until 
hypophosphataemia 
resolved (level 0.8 mmol/L 
or higher) 
Specific 
treatment/management post 
ferric carboxymaltose infusion 
Wolf et al 
(2020)12 
750 mg on day 0 and 
750 mg on day 7 
[117] 
 
Mean 1.07 
65% of patients ≤0.64 at 
day 14 
43% of patients ≤0.64 
mmol/L at day 35 (final 
measuring point) 
No information on 
management/treatment of 
hypophosphataemia 
Ifie et al 
(2019)3  500 mg [1] 0.94 0.43 27 days 
15 doses of 15 mmol phosphate 
infusion across 4 weeks and 
daily oral phosphate, plus 
calcitriol 0.25ug daily, vitamin 
D3 800 U/day 
Schaefer et al 
(2016)13 ≥ 500 mg [55] 
<0.8 mmol/L in 
15% of patients   
3.9% of patients <0.3, 
and 26% >0.3 to <0.5 
(excluding existing the 
15% of patients with pre-
existing 
hypophosphataemia) median of 84 days  
No information on 
management/treatment of 
hypophosphataemia 
Hardy & 
Vandemergel 
(2015)14  mean 2000 mg [78] Mean 1.08  
51% patients a level of 
<0.8, including 13% with 
level <0.32 
Mean hypophosphatemia 
duration of 6 months. Some 
patients received further 
ferric carboxymaltose 
infusions within follow-up 
period 
No information on 
management/treatment of 
hypophosphataemia 
Blazevic et al 
(2014)4 
1000 mg; 3x 1000 
mg; 2x 1000 mg; 3x 
1000 mg [4] Not determined 0.25; 0.32; 0.22; 0.28 
36 days; 28 days; 60 days 
(level = 0.7); unknown 
Iv phosphate, then oral; 
phosphate rich diet; iv 
phosphate and oral phosphate; 
iv phosphate and oral 
phosphate, then calciferol 
Mani et al 
(2010)15  
1500 - 3x 500 mg, 10 
days apart [1] 0.9 0.16 
56 days (paper claims 2 
weeks in text, but graph 
shows 8 weeks) 
iv phosphate (dose not 
disclosed), then oral phosphate 
and calcitriol 
Schouten et 
al (2009)7  918 mg average [8] Mean 1.2  Mean 0.67  
At 42 days post-infusion, 6 
out 8 cases within normal 
range. 
No information on 
management/treatment of 
hypophosphataemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
